Procept BioRobotics reports Q3 results with revenue of $98.3 million and maintains 2026 outlook
Procept BioRobotics announced third‑quarter 2026 revenue of $98.3 million and a loss per share of $0.46. The company said U.S. revenue reached $85.8 million and international revenue $12.5 million, while gross margin improved to 66%. It reaffirmed its 2026 revenue target of $390 million‑$410 million and an adjusted EBITDA loss of $30 million‑$35 million for the year, expecting positive adjusted EBITDA in the fourth quarter.
Why it matters
The company expects a fourth‑quarter adjusted EBITDA of $3 million‑$9 million, which could signal a move toward profitability (the company said). Maintaining the revenue guidance keeps the 2026 growth outlook unchanged for investors.
Key facts
- 1Q3 2026 earnings per share were a loss of $0.46, missing estimates by $0.07. investing.com
- 2Quarter revenue was $98.3 million. investing.com
- 3U.S. revenue increased 16% to $85.8 million. finance.yahoo.com
- 4International revenue climbed 32% to $12.5 million. finance.yahoo.com
- 5Gross margin improved to 66% from 65% a year earlier. finance.yahoo.com
- 6Operating expenses were $92.5 million, up from $77.2 million a year earlier. finance.yahoo.com
Open questions
- Material 2 reports Q3 revenue growth of 19% YoY, while material 3 reports 18% YoY; the same metric on the same basis differs.
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.